Climaterio. Conceptos actuales sobre la carencia estrogénica prolongada y su adecuada substitución
DOI:
https://doi.org/10.51481/amc.v39i2.602Palabras clave:
Menopausia, climaterio, estrógenos, cáncer de mama, cáncer de endometrio, enfermedad cardiovascular, osteoporosisResumen
Los avances en el campo de la medicina han logrado aumentar, en forma dramática, la esperanza de vida durante el presente siglo, mientras que el momento de la menopausia se ha mantenido constante, alrededor de la edad de 50 años. Estos hechos han inducido a un número cada vez mayor de mujeres, a sobrepasar por más de treinta años, el momento de su menopausia, período durante el cual, tendrán la posibilidad de presenciar las múltiples complicaciones que ocurren durante la carencia estrogénica prolongada.
El presente artículo tiene como objetivo el de presentar algunos de los aspectos más relevantes, relacionados con el climaterio y la terapia de reemplazo hormonal, con el fin de que la información brindada sea de utilidad para la mayor parte de los médicos en su práctica diaria. (AMC;39 (2): 7-15) Descriptores: Menopausia, climaterio, estrógenos, cáncer de mama, cáncer de endometrio, enfermedad cardiovascular, osteoporosis.
Descargas
Citas
Bachmann G. The changes before the change. Strategies for the transition to the menopause. Post graduate Med, 1994; 95.
Andrews WC -Transitional years and beyond .0bstet Gynecol, 1995; 85: 1-5
Belchetz PE. Hormonal treatment of postmenopausal women. N Engl J Med, 30: 1063-1071.
Samsioe Goran. Menopause and hormone replacement therapy. 1996 Merit publishing international.
Wild RA, Taylor EL, Knehans A. the gynecologist and the prevention of cardiovascular disease. Am J Obstet Gynecol, 1995; 172: I -13. 6- Andrews WC. Menopause and hormone replacement . Obstet and Gynecol. 1995; 87: 1S
Becker RC.Coronary heart disease in women. Risk and prevention. Coron acute Care-1992, 3
Indicadores de la mortalidad general. Departamento de estadfstica del Ministerio de Salud. Seccicn de Otros programas prioritarios. OPP.2-Agosto 1995. 9- American Heart Association. 1993 Heart and stroke facts statistics.
Wild RA, Taylor E L Knehans A. Menopause. Am J Obstet Gynecol,
Samsioe Goran. Hormone replacement therapy and cardiovascular disease.
Int J Fertil, Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease; a quantitative assesment of the epidemiologic evidence. Prev Med, 1991; 20: 47-63.
Lobo Rogerio. Benefits and risk ofestrogen replacement therapy. Am J Obstet Gynecol. 1995; 173: 982-989.
Henderson BE, Paganini-Hill A, MackTM. Estrogen use and cardiovascular disease. Am J Obstet Gynecol, 1986;154:1181-1186.
Henderson BE, Paganini-Hill A, Ross Rk. Decrease mortality in users of estrogen replacenrnt therapy. Arch Int Med, 1991; 15115-8.
Cormoni-Huntley J, LaCroix AZ, Havlik RJ. Race and sex differentials in the impact of hipertension in the United States. The National Health and Nutrition
Examination Survey I Epidemiologic Follow-up Study. Arch Intern Med, 1989; 149:780-788.
The fith report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. US Department of Health and Human Services. Public Health Service. National Inatitutes of Health. NIH Publ, 1993;N093-1088. 18- StessenJ, Bulpitt CJ, Fagard R, Lijnen R Amery A. The influence of menopause on blood pressure. J Hum Hypertension,1989:3:427-433.
Matthews KA, Meilahn E, Kullre Lh, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary heart disease. N Engl Med, 1989; 321-646.
Bittner V, Oparil S. Hypertension in postrrknopausal women: Brief review Of the litterature and future research directions. Hypertension in postnwnopausal women. (Eds)Springer- Verlag Berlin Heidelberg, 1994:73-87. 21- Staessen JA, Bulpitt CJ, Fagard R, Lunen P, Amery A. The influence of menopause on blood pressure. (Eds)Springer- Verlag Berlin Heidelberg, 1994:1525.
Lobo Rogerio. Cardiovascular disease in wonrn: Influence of hormonal
replacement therapy. (Eds)Springer- Verlag Berlin Heidelberg, 1994:27-44.
Crook David. Postmenopausal hormone replacement therapy, llpopmteiil metabolism, and coronary heart disease. J Cardiovasc Pharmacol. 1996; 28-50.
Writing Group for the PEPI trial. Effects Of estrogen Or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women. JAMA. 1995; 273: 199-218
Barret-Connor E. Sex differences in coronary heart disease. Why are women so superior? Circulation, 1997: 95:252-264.
Sullivan JM, Fowlkes LP. Estrogens, menopause and coronary artery disease. Cardiol Clin, 1995; 14: 105-116.
Sullivan JM. Coronary arteriography in estrogen-treated postmenopausalwomen. Prog Cardiovasc Dis, 1995•,38:211-222.
Grodstein E, Stampfer J. , Colditz G. A., Willet W. C, Manson J. E.. Jotte M Rosner B., Fuchs Ch., Hankinson S. , Hunter D. , Hennekens Ch.. Speizer F Post menopausal hormone therapy and mortality. N Eng J Med. 1997:3361769-1775.
McKinlay SM, Bifano NL, McKinlay JB. Smoking and age at menopause in women. Ann Intem Med, 1985;103:350-356.
Bump RC, McClish DK. Cigarette smoking and urinary incontinence in women. Am J Obstet Gynecol, 1992; 167: 1213-1218.
Christiansen C. Consensus development conference on osteoporosis. Aln J Med, 1993;95.
Sullivan JM. Zwaag RV, Lemp GE Postmenopausal estrogen use and coronary atheroesclerosis. Ann Intern Med, 1988: 108:358-363.
Henderson BE, Paganini-Hill A, Mack TM. Menopausal estrogen theråpy and protection from acute myocardial infarction. AmJ Obstet Gynecol. 1988; 159: 1181-1186.
Manolio TA, Furberg CD, Shemanski L. ASsociations of postmenopausal estrogen use with cardiovascular disease and its risk factor in older wonlen. Circulation. 1993; 88: 2163-2171
Michnovicz JJ, Hershcopf RJ, Naganuma H. Increased 2-Hydroxylation ot estradiol as a possible mechanism for the antiestrogenic effect of cigarette smoking. N Engl Med, 1996; 315: 1305-1309
Cassidenti DL. Vijod MA. Short-term effects of smoking on pharmacokinetic profiles of micronized estradiol in postmenopausal women. Am J Obstet Gynecol
Jensen J. Smoking and postmenopausal hormone replacement. Br J Clin Pract,
Dawood MY, Tldey GF. Menopause. Curr Peobl Obstet Gynecol Fenil. 1993: 16:168-207.
Lindsay R. Bush TL. Grady D, Speroff L, Lobo R. Therapeutic controver» Estrogen replacement menopause. J Clin Endocrinol. 1996; 81:3829-3838.
Christiansen C, Riis Bj.17 B estradiol and continuous norethisterone: A unique treatment for established osteoporosis in the elderly women. J Clin Endocrinol Metab,
Consensus Development Conference: Profilaxis and Treatment
Osteoporosis. Am J Med,
Nassen T, Berglund Ulmsten U. Bone loss in women over years prevented by ultra-low doses of 17 B estradiol. Abstract F88- 80 Int. Congress on Menopause. November 1996. Sydney Australia.
Hesch R. D. The potential influence of estrogen on brain biology and the development of Alzheimer disease. Proceedings of the First European Concensus Development Conference on Menopause.France:Eska. 1996; 69-72.
Ohkura T, Isse K, Akazawa K. Low doses estrogen replacement therapy tor Alzheirner disease in women. The Journal of the American Menopause Sociely
Paganini-Hill A, Henderson VW. Estrogen defficiency and risk of Alzheilner disease in women. Am J Epidemiol, 1994; 140: 256-261
Decreased risk of stroke among postmenopausal hormone users: results frotn national cohort. Arch Intern Med,1993; 153:756-762.
Paganini-Hill A. Estrogen replacement therapy and stroke. Prog Cardiovasc Dissease. 1995.
Stampfer MJ, Colditz GA, Willett WC. Postmenopausal estrogen therapy and cardiovascular disease: ten year follow-up from the Nurses' Health Study. N Engl J Med, 1991.
Birkauser Martin. Contraindications today, indications tomorrow. Consensus development conference on menopause. Edit Eska, 1996:283-291. 51. Crook D, Stevenson JC Transdermal hormone replacement therapy. serulll lipids and lipoproteins. Br J Clin Prac, 1996;86:17-21
Van Erpecum KJ, Van Berge Henegouwen GP Estrogen replacement therapy and risk of hepatobiliary disease in postmenopausal women. Br J Clin Pract.
Youssef Ainmelk. Comparison of low continuous combined estrogen progestoggen regimens in postmenopausal women: a randomized trial. Fertil Body weigth, body fat distribution and hormonal replacement therapy in early postmenopausal wornen. J ClinZ Endocrinol Metab,
SS- Hargrove JT, Osteen KG. An alternative method of hormone replacement
therapy using the natural sex steroids. Infertil Reprod Med, 1995;6:653-674. 56• Hunt K, Vessey M, MC Pherson K. Mortality in a cohort of long users Of hormone replacement therapy: An updated analysis. Br J Obstet Gynecol, 1990.911080-1086.
Colditz GA, Hankinson SE, HunterDJ. Willetwc, Stampfer W, Hennekens CH, Rosner B, Speizer FE. The use of estrogens and progestins and the risk of breast cancer in post menopausal women. N Engl J Med. 1995; 332: 1589-1593.
Kennedy DL, Baum C. Forbes MB. Noncontraceptive estrogens and progestins: use patterns over time. Obstet Gynecol, 1985.
Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: meta-analysis. Obstet Gynecol, 1995; 85: 304-313
Rubin G, PetrsonH, Lee N, Maes E, Wingo P, Becker S. Estrogen replacement therapy and the risk of endometrial cancer. Remaining controversies. Am j Obstet Gynecol, 1995;162: 148-154.
Ettinger B, Golditch 1M, FriedmanG. Gynecologic consequences of long term unopposed estrogen replacement therapy . Maturitas, 1988;10:271-282. 62- Paganini-Esteril, 1996.
Gambacciani M, Cappagli B, Piaggesti L, Simon L, Orlandi R, Genazzani R.
Hill A, Ross R, Henderson B. Endometrial cancer and patterns of use of estrogen replacement therapy: a cohort study. Br J Cancer, 1989; 59: 445-447.
Ettinger B, Selby J, Citron J, VangesselA, Ettinger V, Hendricksson M. Cyclic Hormone replacement therapy using quartely progestin. Obstet Gynecol, 1994; 83: 693-700.
Williams D, Voigt B, Fu Y, Schonenffeld M, Judd H. Assesment of less than a monthly progestin therapy in postmenopausal women given estrogen replacement. Obstet Gynecol, 1994;84:787-793.
Falkerborn M, Persson I, Adami H-O. The risk of acute myocardial infartion after estrogen estrogen-progestogen replacement. Br J Obstet Gynecol, 1992; 99: 821-828.
Grady D, Rubin S. Petitti d, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992: 117:1016-1037. Amstrong B. Estrogens therapy after the menopause - boon or bane?. Med J Aust. 1988; 148: 213-214
Dupont W, Page D. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med, 1991; 151.
Steinberg K, Thacker S, Smith S, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk Of breas! cancer. JAMA, 1991; 265.
Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiologic Rev, 1987.
Schaier C, Byrne C, Keyl P, Brinton L, Sturgeon S, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer Cancer Causes and Control, 1994;5:491-500.
Stanford J, Weiss N, Voigt L, Daling J, Habel L Rossing M. Combined estrogen and progestin replacement hormone therapy in relation to risk of brec•rst cancer in middle- age wome. JAMA, 1995;274: 137-142.
Kaufman DW, Palmer JR, De Mouzon J _ Estrogen replacement therapy, and the risk of breast cancer: results from the cases control surveillance study. Am J Epidemiolol, 1991.
Palmer JR, Rosenberg L, Clarke EA, Miller DR, Shapiro S. Breast cancer risk after estrogen replacement therapy: results from the cases-control surveillance study. Am J Epidemiolol, 1991;13:1386-1395.
Newcomb PA, Longnecker MP, Stored BE. Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiolol. 1995.
Persson l, Yuen J, Bergkvist L, Adami H, Hoover R, Schaierer C. Combined estrogen-progestogen replacement and breast cancer risk. Lancet, 1992; 340: 1044
Sitruk-Ware R. Progestogen use and breast cancer. Abstract A21. 80 Int. Congress on Menopause. November 1996. Sydney Australia.
Anderson PW. The clinical promise of the selective estrogen receptor modulator, raloxifene HCI and the postmenopausal women. Abstract SIS. 80 Int. Congress on Menopause. November 1996. Sydney Australia.
Nachtigall LE. El desafio del cumplimiento de la terapia hormonal de reemplazo. Perspectivas Internacionales sobre el Tratamiento de la Menopausia. 1994.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2010 Acta Médica Costarricense
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-SinDerivadas 4.0.
Los autores que publican en la revista Acta Médica Costarricense pueden distribuir, copiar, remezclar, retocar, leer, descargar, imprimir, buscar y crear a partir de su obra de modo no comercial, indicando los créditos a la revista y sus autores y compartir su obra en las mismas condiciones. Para ello se aplica la licencia Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0 Internacional(CC BY-NC-SA 4.0)
